Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 17/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30273059 | 1.00 | GRM5 (1.00) | GRM5CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL1803964 | 0.98 | GRM5 (0.97) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL7425347 | 0.86 | GRM5 (1.00) | GRM5CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL7419836 | 0.85 | GRM5 (0.97) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL11966024 | 0.83 | GRM5 (0.70) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL11966077 | 0.83 | GRM5 (0.70) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL5653485 | 0.83 | GRM5 (1.00) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL4158461 | 0.83 | GRM5 (1.00) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL3458329 | 0.82 | GRM5 (1.00) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL11966074 | 0.82 | GRM5 (0.68) | GRM5CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 382 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | ORPHELION AB (SE) | 2026-05-07 | — | — | US | claimed |
| EP-4583872-A1 | MGLUR5 RECEPTOR ANTAGONISTS FOR USE IN PREVENTION AND/OR TREATMENT OF BONE MARROW LESIONS (BML) AND/OR OSTEOPOROSIS, CARTILAGE LOSS, OSTEOSCLEROSIS, OSTEITIS IN A MAMMAL | ORPHELION AB (SE) | 2025-07-16 | — | — | EP | claimed |
| US-20240408090-A1 | Methods Of Treating Dyskinesia And Related Disorders | MELIOR PHARMACEUTICALS II, LLC | 2024-12-12 | — | — | US | claimed |
| US-12048697-B2 | Methods of treating dyskinesia and related disorders | MELIOR PHARMACEUTICALS II, LLC (US) | 2024-07-30 | — | — | US | claimed |
| WO-2024088712-A1 | MGLUR5 RECEPTOR ANTAGONISTS FOR USE IN PREVENTION AND/OR TREATMENT OF BONE MARROW LESIONS (BML) AND/OR OSTEOPOROSIS, CARTILAGE LOSS, OSTEOSCLEROSIS, OSTEITIS IN A MAMMAL | ORPHELION AB (SE) | 2024-05-02 | — | — | WO | claimed |
| US-20220331320-A1 | Methods Of Treating Dyskinesia And Related Disorders | MELIOR PHARMACEUTICALS II, LLC | 2022-10-20 | — | — | US | claimed |
| US-20190328736-A1 | Methods Of Treating Dyskinesia And Related Disorders | CAVALRY FUND I LP | 2019-10-31 | — | — | US | claimed |
| EP-3160464-A1 | USE OF BUSPIRONE METABOLITES | Contera Pharma APS (DK) | 2017-05-03 | — | — | EP | claimed |
| US-20160257957-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM SPECTRUM DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-09-08 | — | — | US | claimed |
| EP-2544688-B1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ANGELMAN SYNDROME | HARVARD COLLEGE (US) | 2016-09-07 | — | — | EP | claimed |
| US-20090192199-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-30 | — | — | US | claimed |
| WO-2009076529-A1 | SMALL MOLECULES FOR NEURONAL DIFFERENTIATION OF EMBRYONIC STEM CELLS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2009-06-18 | — | — | WO | claimed |
| EP-2010174-A2 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | The Regents of the University of California (US) | 2009-01-07 | — | — | EP | claimed |
| WO-2007124348-A2 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-01 | — | — | WO | claimed |
| US-20070160850-A1 | Fluoro-compound water repellent composition for wood product dimensional stability | OSMOSE, INC. (US) | 2007-07-12 | — | — | US | claimed |
| WO-2007067648-A2 | FLUORO-COMPOUND WATER REPELLENT COMPOSITION FOR WOOD PRODUCT DIMENSIONAL STABILITY | OSMOSE, INC. (US) | 2007-06-14 | — | — | WO | claimed |
| JP-2006516587-A | — | — | 2006-07-06 | — | — | JP | claimed |
| EP-1599204-A2 | SELECTIVE MGLU5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT | Recordati Ireland Limited (IE) | 2005-11-30 | — | — | EP | claimed |
| US-20040215284-A1 | Treatment of neuromuscular dysfunction of the lower urinary tract with selective mGlu5 antagonists | RECORDATI S.A. | 2004-10-28 | — | — | US | claimed |
| WO-2004067002-A2 | SELECTIVE mGlu5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT | RECORDATI IRELAND LIMITED (IE) | 2004-08-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220331320-A1 | Methods Of Treating Dyskinesia And Related Disorders | SLC6A3, CHAT, ACHE | GRM5 319/4885CYP1A2 2019/4885CYP2D6 943/4885 |
| US-20240408090-A1 | Methods Of Treating Dyskinesia And Related Disorders | SLC6A3, CHAT, ACHE | GRM5 319/4885CYP1A2 2019/4885CYP2D6 943/4885 |
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | GRM5, OPRL1, GRM1 | GRM5 1/4885CYP1A2 4061/4885CYP2D6 3131/4885 |
| US-20090192199-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | GRM1, GRM2, GRIN1 | GRM5 13/4885CYP1A2 4845/4885CYP2D6 4853/4885 |
| US-12048697-B2 | Methods of treating dyskinesia and related disorders | SLC6A3, CHAT, ACHE | GRM5 319/4885CYP1A2 2019/4885CYP2D6 943/4885 |
| US-20190328736-A1 | Methods Of Treating Dyskinesia And Related Disorders | SLC6A3, CHAT, ACHE | GRM5 319/4885CYP1A2 2019/4885CYP2D6 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.